Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
ASRT · 10-Q filed May 8, 2026

ASRT earnings analysis

What we found in ASRT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

Assertio Holdings, Inc. reported total revenues of $9.9 million for Q1 2026, down significantly from $26.5 million in Q1 2025, reflecting a drastic decrease in product sales, particularly from ROLVEDON. The company incurred a loss from operations of $18.5 million and is experiencing challenges due to the recent asset sale that has left ROLVEDON as its only commercial product. Management expressed concerns regarding their ability to maintain profitability amid operational restructuring and intensified market competition.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Revenue Decline
Total revenue fell to $9.9 million in Q1 2026, down from $26.5 million in Q1 2025, a decline of 62.7%.
Gross Margin Decrease
Gross margin plummeted as a percentage, although the exact percentage is unspecified; operating margin also collapsed to -185.3% in Q1 2026.
Operational Losses
Loss from operations was $18.5 million for Q1 2026, compared to $13.2 million in Q1 2025.
Cash Flow Improvement
Operating cash flow showed substantial improvement, at $8.6 million for Q1 2026, compared to cash used of $12.5 million in Q1 2025.
Asset Sale Completion
The divestment of non-ROLVEDON assets to Cosette was completed for $35 million, signaling a major shift in product focus.
Reduction in Debt Service Exposure
Total interest expense increased slightly to $775,000 in Q1 2026, from $765,000 in Q1 2025.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Weak Product Sales
ROLVEDON sales sharply decreased from $13.1 million to $0.5 million YoY, highlighting vulnerability.
Pending Merger Impacts
Failure to complete the pending merger with Garda Therapeutics could negatively impact stock price and operational continuity.
High Cash Burn Rate
Operating losses remain a concern; cash burn requires attention even with cash reserves at $71.6 million.
Guidance

What they said about what is next.

Outlook deferred to the earnings press release / call.

How we read the filing overall

The filing reads worse than the one before it.

One reading of one document. It is not advice, and it is not a forecast.

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing ASRT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever